Market Cap : 60.6 B | Enterprise Value : 68.84 B | PE Ratio : 72.99 | PB Ratio : 3.50 |
---|
NYSE:BSX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:BSX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Boston Scientific's Enterprise Value is $68,835 Mil. Boston Scientific's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 was $579 Mil. Therefore, Boston Scientific's EV-to-FCF for today is 118.89.
The historical rank and industry rank for Boston Scientific's EV-to-FCF or its related term are showing as below:
During the past 13 years, the highest EV-to-FCF of Boston Scientific was 449.09. The lowest was -10643.87. And the median was 44.28.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-08-12), Boston Scientific's stock price is $42.33. Boston Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $0.580. Therefore, Boston Scientific's PE Ratio for today is 72.98.
For the Medical Devices subindustry, Boston Scientific's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Boston Scientific's EV-to-FCF falls into.
Boston Scientific's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 68835.214 | / | 579 | |
= | 118.89 |
Boston Scientific's current Enterprise Value is $68,835 Mil.
Boston Scientific's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $579 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Boston Scientific's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 42.33 | / | 0.580 | |
= | 72.98 |
Boston Scientific's share price for today is $42.33.
Boston Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Boston Scientific's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Wichmann David S | director | UNITEDHEALTH GROUP INC 9900 BREN RD E MINNETONKA MN 55343 |
Brown Vance R | officer: SVP, GC and Corp. Secretary | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Olson Scott | officer: SVP & Pres, Rhythm Management | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Scanlon Meghan | officer: SVP,Pres,Urology Pelvic Health | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Monson Jonathan | officer: VP, Corp Controller and CAO | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Fujimori Yoshiaki | director | 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
James Donna | director | ONE MIRANOVA PLACE SUITE 1040 COLUMBUS OH 43215 |
Zane Ellen M | director | C/O TUFTS-NEW ENGLAND MEDICAL CENTER 750 WASHINGTON STREET, TUFTS-NEMC #451 BOSTON MA 02111 |
Sununu John E | director | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Connors Nelda J | director | BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 |
Ludwig Edward J | director | C/O BECTON DICKERSON & CO 1 BECTON DR FRANKLIN LAKES NJ 07417 |
Roux David J | director | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
Dockendorff Charles J | director | COVIDIEN LTD. 15 HAMPSHIRE STREET MANSFIELD MA 02048 |
Macmillan Stephen P | director | 250 CAMPUS DRIVE MARLBOROUGH MA 01752 |
Wang Xin Warren | officer: SVP and Pres, Asia Pacific | C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 |
From GuruFocus
Other Sources
By Zacks 2021-12-21
By Zacks 2022-02-01
By Zacks 2022-02-02
By Seekingalpha 2022-01-26
By tipranks.com 2022-02-11
By Zacks 2021-12-21
By Zacks 2022-02-11
By Zacks 2022-01-24
By Zacks 2022-01-26